ClinicalTrials.gg
Not yet recruitingNCT07033299Updated Jun 24, 2025

The Safety, Efficacy, and Cellular Metabolic Kinetics of CT1192 in Treating Patients With Anti Neutrophil Cytoplasmic Antibody Associated Vasculitis

A Phase 1 interventional study of CAR-T Therapy in ANCA Associated Vasculitis (AAV), sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-06-24.

Sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 57 studies in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis with a site in China — 42 open to participants now, 46 under way, 1 of them phase 3. Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · China.

Planned enrollment
37th of 52
12 · median 18
Started
2025
with 20 others
Phase 1
31 of 57
26 open now
Primary completion
2026-12
later than 13 of 45 live
Registered
36th of 57
by date

Among the 57 studies in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis with a site in China, this one is the 37th largest by planned enrollment of the 52 interventional ones that give a count, is one of 21 that started in 2025, is one of 31 in phase 1, reaches primary completion later than 13 of the 45 other live ones, and was the 36th registered.

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

158 studies on the registry are indexed under Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; 76 are open to participants now.

Browse Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis studies →

Open to participants now

42 of the 57 studies in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis with a site in China are open now. Recruiting first, the newest first:

37 more — sign in →

All 42 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 56 Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis studies recruiting now, 21 (38%) set no upper age limit and 28 (50%) stop at 75 or younger; 9 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis with a site in China, or all of them as a file.
02

Study summary

A clinical study exploring the safety, efficacy, and cellular metabolic kinetics of universal CD19/20 CAR-T cell injection in anti neutrophil cytoplasmic antibody associated vasculitis.

This study is a single arm, open label, exploratory dose escalation clinical trial aimed at evaluating the safety, efficacy, and cellular metabolic dynamics of CT1192 cells in patients with ANCA associated vasculitis.

Read the detailed description

The study is divided into dose escalation stage and dose expansion stage. Dose escalation stage The dose escalation is tentatively set at three dose levels, namely 3.0 × 108, 4.5 × 108, and 6.0 × 108 CAR-CD19/CD20+T cells. The expected target toxicity probability for the maximum tolerated dose is 30%, with a planned enrollment of approximately 12 participants. The number of participants in each dose group is subject to actual circumstances. During the experiment, researchers and collaborators will jointly negotiate whether to increase or decrease the dosage based on the participants' cellular metabolic characteristics, safety, tolerability, and preliminary efficacy data, whether to increase to the set highest dose group or produce the maximum cell quantity that can be supplied, and whether to explore new dose levels within the explored dose range (allowing for dose adjustments), in order to determine the possible recommended therapeutic dose (RD).

The DLT observation period is 28 days after the first infusion. If the treatment needs to be withdrawn before 28 days after infusion due to disease progression or other reasons, and no significant CAR-T cell expansion is detected or CAR-T therapy is ineffective, and the DLT related AE events determined by the researchers may not be related to the product, the DLT observation period can be completed in advance. When there are safety risks that need to be discussed during each dose escalation, researchers and collaborators can decide when to enter the next dose group based on the safety, tolerability, and metabolic kinetics of CT1192 cells of the participants. Participants in the same dose group need to receive cell infusions at 14 day intervals, and subsequent participants can only receive cell infusions when no significant safety risks (including DLT) are observed.

Dose expansion stage Based on the results of the dose escalation phase, one or more dose groups may be selected for dose expansion to further explore the efficacy and safety in ANCA related vasculitis patients. Each dose group and queue are planned to include a maximum of 9 cases, and the specific number of participants is subject to actual conditions. DLT will not be observed during the dose expansion phase, and other research processes will be the same as during the dose escalation phase. Researchers and collaborators will continue to monitor the safety data of the entire dose expansion phase and make entry and exit decisions as necessary.

03

Conditions studied

  • ANCA Associated Vasculitis (AAV)

Keywords

  • CT1192
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ANCA associated vasculitis that meets the 2022 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) criteria, including microscopic polyangitis, granulomatous polyangitis, and eosinophilic granulomatous polyangitis;
  2. Voluntarily sign the Form (ICF); When signing the ICF, the age range is between 18 and 60 years old (including 18 and 60 years old), with no gender restrictions;
  3. No systemic active infections (such as infectious pneumonia or tuberculosis) within the first 2 weeks of screening;
  4. Women with fertility (defined as all physiologically capable women) must agree to use effective methods from at least 28 days prior to the start of vaginal dialysis to 1 year after CT1192 infusion. Egg donation is strictly prohibited within 1 year after receiving the study treatment infusion during the study period. Male partners with fertility must agree to use effective barrier contraception methods from the start of lymphatic dialysis until 1 year after CT1192 reinfusion, and should not donate semen or sperm throughout the entire study period;
  5. Women with fertility must test negative for serum β - human chorionic gonadotropin (β - hCG) during screening and within 48 hours prior to gonorrhea treatment;
  6. Prior to screening, routine treatment ( combined with ) must have been received for at least 6 months but still ineffective, or disease recurrence after remission (BVAS>0); During screening, ANCA related antibodies were positive for p-ANCA or c-ANCA;
  7. Birmingham vasculitis activity score (BVAS) ≥ 15 points during the screening period;
  8. Adequate organ function:

1) Renal function: defined as a rate (Cockcroft Gault) calculated without hydration assistance of ≥ 50 mL/min; 2) Bone marrow function: defined as (ANC) ≥ 1.0 × 109/L and (Hb) ≥ 90 g/L. Blood transfusions and growth factors must not be used to meet these requirements within 7 days prior to eligibility screening; 3) Liver function: defined as (ALT) and aspartate aminotransferase (AST) ≤ 2 x (ULN), total ≤ 2 x upper limit of normal (ULN) 4) Coagulation function: defined as (INR) or Activated Partial Thromboplastin Time (APTT) ≤ 1.5 × ULN; 5) Pulmonary function: Blood oxygen saturation (SpO2) ≥ 92% in indoor air (measured by pulse oximeter); 6) Cardiac function: defined as a (LVEF) of ≥ 50% evaluated by echocardiography (ECHO) within the first 8 weeks of screening.

Exclusion criteria

Exclusion Criteria:

  1. Previously received CAR-T cell or other genetically modified T cell therapy, or had a history of major organ transplantation (such as heart, lung, kidney, liver) or hematopoietic stem cell/bone marrow transplantation;
  2. Screening for CD20 monoclonal antibodies such as rituximab used within the previous 6 months;
  3. Use other biological agents such as Mabolizumab during the screening period of 12 weeks;
  4. Allergic or intolerant reactions to Qinglin drugs, tocilizumab, or life-threatening allergic reactions, reactions, or intolerance to CT1192 preparations or their (including dimethyl sulfoxide (DMSO)), or previous history of other severe allergies such as anaphylactic shock;
  5. Hormone use ≥ 10 mg/day of prednisone (or equivalent) within 2 weeks prior to CT1192 infusion, with the use of physiological substitutes, topical and inhaled allowed;
  6. Received agents that affect T cells (mycophenolate mofetil, methotrexate, cyclosporine, azathioprine, leflunomide, tacrolimus) within 2 weeks prior to CT1192 infusion;
  7. Have received JAK inhibitors (tofacitinib, baritinib tablets, lukatinib, etc.) within 2 weeks prior to CT1192 infusion;
  8. Individuals with a history of ≥ grade 2 bleeding or requiring long-term anticoagulant therapy within the 30 days prior to screening; Within 30 days prior to screening, plasma exchange, plasma separation, and hemodialysis treatments have been performed;

10. Have received attenuated , inactivated vaccine or RNA vaccine within one month before screening; 11. Suffering from malignant tumors within 2 years prior to signing the ICF. Except for the following situations: non melanoma skin cancer that has undergone radical treatment, local prostate cancer, cervical carcinoma in situ confirmed by or squamous intraepithelial lesions detected by cervical smear, and breast carcinoma in situ that has been completely removed; 12. If a major surgery has been performed within 4 weeks prior to signing the form, or if a major surgery is planned during the study period, the researcher believes that it would pose unacceptable risks to the participants; During screening, there may be , syphilis infection, active virus infection (HBsAg positive and HBV-DNA above the detection limit), or active virus infection (HCV antibody and HCV-RNA positive); 14. Individuals with central nervous system diseases prior to screening include but are not limited to: cerebrovascular accidents, encephalitis, epilepsy, seizures/convulsions, stroke, severe brain injury, dementia, Parkinson's disease, cerebellar diseases, central nervous system vasculitis, cognitive dysfunction, organic brain syndrome, or psychiatric disorders; 15. History of any of the following cardiovascular diseases within one month prior to screening: Grade III or IV heart failure defined by the (NYHA), myocardial infarction, unstable angina, uncontrolled or symptomatic atrial arrhythmias, any ventricular arrhythmias, or other heart diseases; 16. Participate in other clinical studies within the first 3 months of screening or still within the five half lives after the last medication; 17. If there is a history or evidence of suicidal thoughts within the previous 6 months, or any suicidal behavior within the previous 12 months, the researcher believes that there is a significant risk of suicide; 18. Pregnant or lactating women; 19. The researchers determined that the participants had poor compliance, were unable or unwilling to comply with the requirements of the study protocol, or were not suitable to participate in this clinical study for other reasons.

Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    CT1192 CAR-T cells Injection

    CT1192 cells infusion

    Biological: CAR-T Therapy

Interventions

  • BiologicalCAR-T Therapy

    CT1192 cells infusion

06

What researchers measure

Primary outcomes

  1. Evaluate the safety and tolerability of CT1192 in patients with ANCA associated vasculitis

    The incidence and severity of dose limiting toxicity (DLT), adverse events (AE), serious adverse events (SAE), and AESI (adverse events of particular concern);

    Time frame: : Within 28 days after infusion for DLT, within 180 days after infusion fOr AE/SAEwithin 12 months after infusion for AESl]

  2. Evaluate the maximum tolerable dose (MTD) and/or dose range of CT1192

    CT1192 MTD and/or dose range

    Time frame: After medication to day 28

Secondary outcomes

  1. After treatment, the Birmingham vasculitis activity score (bvas) changed from baseline

    Preliminary evaluation of the effectiveness of CT1192 in patients with ANCA related vasculitis. Changes in Birmingham vasculitis activity score (BVAS) compared to baseline at 3 months and other time points (1, 6, 9, and 12 months) after medication.

    Time frame: At 1, 3, 6, 9, and 12 months after medication

  2. Changes of vasculitis damage index (VDI) from baseline after medication

    Preliminary evaluation of the effectiveness of CT1192 in patients with ANCA related vasculitis. Vasculitis damage index (VDI) and changes from baseline at 3 months and other time points (1, 6, 9, and 12 months) after medication.

    Time frame: At 1, 3, 6, 9, and 12 months after medication

  3. Changes of serum markers (MPO-ANCA or PR3-ANCA) in ANCA related vasculitis after medication

    Preliminary evaluation of the effectiveness of CT1192 in patients with ANCA related vasculitis. Changes in serum markers of ANCA related vasculitis (MPO-ANCA or PR3-ANCA) levels at 1, 3, 6, 9, and 12 months after medication.

    Time frame: At 1, 3, 6, 9, and 12 months after medication

  4. Changes of immunoglobulin (IgG, IgM, IgA, IgE) levels after medication

    Preliminary evaluation of the effectiveness of CT1192 in patients with ANCA related vasculitis. Changes in immunoglobulin (IgG, IgM, IgA, IgE) levels at 1, 3, 6, 9, and 12 months after medication.

    Time frame: At 1, 3, 6, 9, and 12 months after medication

  5. Proportion of patients without other ANCA related vasculitis therapy after medication

    Preliminary evaluation of the effectiveness of CT1192 in patients with ANCA related vasculitis. The proportion of patients without other ANCA related vasculitis therapies at 1, 3, 6, 9, and 12 months after medication.

    Time frame: At 1, 3, 6, 9, and 12 months after medication

  6. The change value of post medication Health Assessment Questionnaire Disability Index (HAQ-DI) from baseline

    Preliminary evaluation of the effectiveness of CT1192 in patients with ANCA related vasculitis. Changes in Health Assessment Questionnaire Disability Index (HAQ-DI) from baseline at 1, 3, 6, 9, and 12 months after medication.

    Time frame: At 1, 3, 6, 9, and 12 months after medication

  7. The level of CT1192 gene copy number in the blood

    Objective to evaluate the cell kinetics of ct1192 in ANCA associated vasculitis participants. The copy number and duration of ct1192 gene in blood were observed.

    Time frame: Within 1 year after CAR-T cell infusion

  8. Duration of CT1192 gene copy number in blood

    Objective to evaluate the cell kinetics of ct1192 in ANCA associated vasculitis participants. The copy number and duration of ct1192 gene in blood were observed.

    Time frame: Within 1 year after CAR-T cell infusion

  9. Changes of B cell functional subsets (initial B cells, memory B cells, plasma cells) after ct1192 reinfusion

    Evaluate the pharmacological (PD) characteristics of CT1192 in participants with ANCA associated vasculitis, and assess the changes in B cell functional subgroups (initial B cells, memory B cells, plasma cells) after CT1192 reinfusion.

    Time frame: Within 1 year after CAR-T cell infusion

  10. Changes in cytokine levels (IL-2, IL-6, TNF - α, IFN - α) after CT1192 cell infusion

    Evaluate the pharmacodynamic (PD) characteristics of CT1192 in participants with ANCA associated vasculitis and the changes in cytokine levels after CT1192 reinfusion.

    Time frame: Within 1 year after CAR-T cell infusion

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2025; primary completion for Dec 2026, 17 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2025
First posted
Jun 24, 2025
StartEst.
Jul 1, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Mar 31, 2027
Last update
Jun 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07033299
Collaborators
CARsgen Therapeutics Co., Ltd.
Responsible party
Qiubai Li (Director, Head of Department of Rheumatology and Immunology, Principal Investigator, Professor, Wuhan Union Hospital, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology) — Principal investigator
First posted
Jun 24, 2025
Start date
Jul 1, 2025 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Jun 24, 2025

Study contacts

Qiubai Li
Contact
qiubaili@hust.edu.cn
Professor 85726808 Ext.027

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion